Background

Myopia is a global problem. The rising prevalence and the risks of sight-threatening ocular pathology associated with myopia are well documented. By 2050, it is predicted that half the world’s population will have myopia, with nearly one billion at high risk of sight threatening ocular pathology. In the UK, the prevalence of myopia in children aged between 10–16 years has more than doubled over the last 50 years, and children are becoming myopic at a younger age. Given this backdrop, we felt it was crucial to begin to understand and tackle these issues head on as a united sector. To facilitate this, we held a roundtable event with researchers and clinicians in the field to consider the current evidence on childhood and adult myopia management. The aim was to reach a consensus about what the current evidence supported with regard to practice in this area.

1.89 billion people

are currently affected by myopia

3 in 10 people

are short-sighted in the UK, and the numbers are growing

Nearly 5 billion people

will be myopic by 2050

Source: Acuity, Focus on Myopia, August 2018

How might the findings affect you in practice?

• All myopia control interventions need to be underpinned by patients’ explicit consent, involving clear provision of information and accurate records of the discussions leading to the consent being given.
   
• If you are going to recommend interventions, you need to take responsibility for ensuring that you keep up-to-date with the evidence relating to myopia management, and ensure that you understand the issues involved in obtaining consent.
   
• You must discuss the option of no treatment and should record that discussion.
   
• You should discuss the mechanism you would use to measure outcomes – measurement of axial length being the best method.
   
• You should make clear that it is difficult to predict whether, and to what extent, an individual would benefit from any interventions, and that it is impossible to show what might have happened without any intervention. 
   
• Your practices must have an adverse event reporting scheme to track safety issues and build the evidence base data set for future use.

The College developed myopia management guidance to help you decide what:

• you should tell patients and their parents about what treatment is available, for whom it is suitable, how effective it might be and the probability of it being effective, and what the short-term and long-term risks and benefits are likely to be
   
• you should do if you are already offering myopia management interventions.